BAM
NVCR icon

Bullseye Asset Management’s NovoCure NVCR Stock Holding History

Bullseye Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-53,745
Closed -$9.3M – 99
2020
Q4 		$9.3M Buy
53,745
+7,514
+16% +$1.03M 3.47% 1
2020
Q3 		$5.15M Buy
46,231
+1,070
+2% +$85.6K 2.34% 9
2020
Q2 		$2.68M Buy
+45,161
New +$2.97M 1.43% 25

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bullseye Asset Management's NVCR Position: Q1 2021 in Review

Bullseye Asset Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 53,745 shares — an estimated $9.3M sold.

Bullseye Asset Management first reported a position in NVCR in Q2 2020 and held it in 3 quarters. The position peaked at $9.3M in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Bullseye Asset Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Bullseye Asset Management sold 53,745 NovoCure shares in Q1 2021, an estimated $9.3M.
  • Bullseye Asset Management first reported a position in NovoCure in Q2 2020 and held it in 3 quarters.
  • Bullseye Asset Management's NovoCure position peaked at $9.3M in Q4 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Bullseye Asset Management's 13F filing for Q1 2021, filed 13 May 2021.